Clinical trial · Observational
Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy
A Cohort Study of Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy by Applying Wearable Electrocardiogram
NCT05454878CI-TRIAL-00059622unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atrial Fibrillation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence
- timeFrame
- 1 year after the first course of chemotherapy
- description
- Incidence of atrial fibrillation after chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. At least 18 years old; 2. Concurrent chemotherapy on patients with new-onset lymphoma: chemotherapy regimens containing anthracyclines; 3. The subject voluntarily signed the informed consent. Exclusion Criteria: 1. With heart failure, acute stroke or acute coronary syndrome within 3 months before admission 2. With Atrial fibrillation on admission 3. Patient after pacemaker surgery 4. With mental illness or mentally disabled 5. Patients that the investigator considers as unsuitable for this test
References
Publications (0)
Data not yet available
No reference posted for this study.